144 related articles for article (PubMed ID: 9806108)
1. Edrecolomab (monoclonal antibody 17-1A).
Adkins JC; Spencer CM
Drugs; 1998 Oct; 56(4):619-26; discussion 627-8. PubMed ID: 9806108
[TBL] [Abstract][Full Text] [Related]
2. Update of clinical trials with edrecolomab: a monoclonal antibody therapy for colorectal cancer.
Haller DG
Semin Oncol; 2001 Feb; 28(1 Suppl 1):25-30. PubMed ID: 11273586
[TBL] [Abstract][Full Text] [Related]
3. Technology evaluation: edrecolomab, Centocor Inc.
Abicht A; Lochmüller H
Curr Opin Mol Ther; 2000 Oct; 2(5):593-600. PubMed ID: 11249762
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma.
Schwartzberg LS
Crit Rev Oncol Hematol; 2001 Oct; 40(1):17-24. PubMed ID: 11578913
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment.
Naundorf S; Preithner S; Mayer P; Lippold S; Wolf A; Hanakam F; Fichtner I; Kufer P; Raum T; Riethmüller G; Baeuerle PA; Dreier T
Int J Cancer; 2002 Jul; 100(1):101-10. PubMed ID: 12115595
[TBL] [Abstract][Full Text] [Related]
6. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study.
Punt CJ; Nagy A; Douillard JY; Figer A; Skovsgaard T; Monson J; Barone C; Fountzilas G; Riess H; Moylan E; Jones D; Dethling J; Colman J; Coward L; MacGregor S
Lancet; 2002 Aug; 360(9334):671-7. PubMed ID: 12241873
[TBL] [Abstract][Full Text] [Related]
7. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group.
Riethmüller G; Schneider-Gädicke E; Schlimok G; Schmiegel W; Raab R; Höffken K; Gruber R; Pichlmaier H; Hirche H; Pichlmayr R
Lancet; 1994 May; 343(8907):1177-83. PubMed ID: 7909866
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow.
Braun S; Hepp F; Kentenich CR; Janni W; Pantel K; Riethmüller G; Willgeroth F; Sommer HL
Clin Cancer Res; 1999 Dec; 5(12):3999-4004. PubMed ID: 10632331
[TBL] [Abstract][Full Text] [Related]
9. EpCAM: A new therapeutic target for an old cancer antigen.
Armstrong A; Eck SL
Cancer Biol Ther; 2003; 2(4):320-6. PubMed ID: 14508099
[TBL] [Abstract][Full Text] [Related]
10. The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study.
Tsavaris NB; Katsoulas HL; Kosmas C; Papalambros E; Gouveris P; Papantoniou N; Rokana S; Kosmas N; Skopeliti M; Tsitsilonis OE
Oncology; 2004; 67(5-6):403-10. PubMed ID: 15713997
[TBL] [Abstract][Full Text] [Related]
11. Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: reduction of 17-1A-positive disseminated tumour cells.
Kirchner EM; Gerhards R; Voigtmann R
Ann Oncol; 2002 Jul; 13(7):1044-8. PubMed ID: 12176782
[TBL] [Abstract][Full Text] [Related]
12. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A.
Gruber R; van Haarlem LJ; Warnaar SO; Holz E; Riethmüller G
Cancer Res; 2000 Apr; 60(7):1921-6. PubMed ID: 10766181
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients.
Staib L; Birebent B; Somasundaram R; Purev E; Braumüller H; Leeser C; Küttner N; Li W; Zhu D; Diao J; Wunner W; Speicher D; Beger HG; Song H; Herlyn D
Int J Cancer; 2001 Apr; 92(1):79-87. PubMed ID: 11279610
[TBL] [Abstract][Full Text] [Related]
14. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
Weiner LM; Moldofsky PJ; Gatenby RA; O'Dwyer J; O'Brien J; Litwin S; Comis RL
Cancer Res; 1988 May; 48(9):2568-73. PubMed ID: 3128400
[TBL] [Abstract][Full Text] [Related]
15. Drug evaluation: IGN-101--an anti-EpCAM murine antibody vaccine for cancer.
Kirman I
Curr Opin Mol Ther; 2006 Aug; 8(4):358-65. PubMed ID: 16955700
[TBL] [Abstract][Full Text] [Related]
16. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial of CO17-1A monoclonal antibody.
Lobuglio AF; Saleh M; Peterson L; Wheeler R; Carrano R; Huster W; Khazaeli MB
Hybridoma; 1986 Jul; 5 Suppl 1():S117-23. PubMed ID: 3488950
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulation therapy in colorectal carcinoma.
Yip D; Strickland AH; Karapetis CS; Hawkins CA; Harper PG
Cancer Treat Rev; 2000 Jun; 26(3):169-90. PubMed ID: 10814560
[TBL] [Abstract][Full Text] [Related]
20. EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges.
Chaudry MA; Sales K; Ruf P; Lindhofer H; Winslet MC
Br J Cancer; 2007 Apr; 96(7):1013-9. PubMed ID: 17325709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
